ASCO Genitourinary Cancers Symposium | Conference

Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER
February 25, 2021

In the phase 3 CheckMate 9ER trial, investigators found that nivolumab plus cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously untreated advanced renal cell carcinoma.

Michael Szarek, PhD, on the Rationale Behind Conducting a Q-TWiST Analysis of the Phase 3 TIVO-3 Study
February 22, 2021

A Q-TWiST analysis evaluated the use of tivozanib versus sorafenib among patients with advanced renal cell carcinoma included in the phase 3 TIVO-3 study.

Toni Choueiri, MD, on How New Data Impact the Standard of Care for RCC
February 20, 2021

An expert discusses how new data from the phase 3 CheckMate 9ER trial impact therapy choice in previously untreated advanced renal cell carcinoma.